Design Therapeutics (DSGN) Amortization of Deferred Charges (2020)

Design Therapeutics' (DSGN) quarterly Amortization of Deferred Charges came in at $12000.0 in Q1 2020.

Design Therapeutics (DSGN) Amortization of Deferred Charges (2020) Analysis & Trends

Design Therapeutics has disclosed Amortization of Deferred Charges across 1 years of filings, most recently posting $12000.0 for Q1 2020.

Amortization of Deferred Charges for Q1 2020 came in at $12000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2020 was $12000.0 (changed N/A YoY), and the FY2020 annual result was $12000.0, changed N/A from the prior year.
Amortization of Deferred Charges came in at $12000.0 for Q1 2020 at Design Therapeutics.
In the past five years, Amortization of Deferred Charges ranged from a high of $12000.0 in Q1 2020 to a low of $12000.0 in Q1 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Design Therapeutics	763.94 Mn	541.11 Mn	-

Download Data

Date	Value
Mar 31, 2020	12,000.00
Mar 31, 2020	12,000.00